Using another detection method, Waser et al
Theres a clinical emphasis on collaborative, patient-tailored approaches: GLP-1 use should be based on shared decision-making of the patient with the care team Healthcare staff need to be aware of factors like: Elevated symptom prevalence during the titration phase Dose magnitude and how side effect prevalence increases accordingly Daily oral vs
8 Just like GLP-1, the GIP (glucose-dependent insulinotropic polypeptide) pathway is activated primarily after meals, but performs different functions
To those who are still bleating that we should keep trying diet and exercise before resorting to use of anti obesity medications or that we can maintain long term weight loss effected by use of medication by ceasing medication and relying on diet and exercise alone- please look up all the research which shows that lifestyle intervention alone can only effect 5-7% weight loss and this weight will also be regained in the next year or two
Sources: GLP-1 Agonists: What They Are, How They Work & Side Effects (clevelandclinic.org) GLP-1 Medications: Everything You Need to Know (healthline.com) Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 | FDA FDA Approves New Medication for Chronic Weight Management | FDA Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients (pharmacytimes.com) Popular GLP-1 Agonists List, Drug Prices and Medication Information - GoodRx Relationship between diet/exercise and pharmacotherapy to enhance the GLP1 levels in type 2 diabetes - PMC (nih.gov)
Proteins take a while to digest, and therefore reach those GLP-1-secreting cells that are further along in the intestinal tract
